Israel Englander Editas Medicine, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,350,856 shares of EDIT stock, worth $8.08 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,350,856

Previous 2,459,629 36.23%

Holding current value

$8.08 Million

Previous $11.5 Million 0.52%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $3.02 Million - $5.31 Million	891,227 Added 36.23%	3,350,856 $11.4 Million
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $1.04 Million - $1.62 Million	223,012 Added 9.97%	2,459,629 $11.5 Million
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $4.54 Million - $7.15 Million	645,808 Added 40.6%	2,236,617 $16.6 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $1.38 Million - $2.46 Million	220,987 Added 16.13%	1,590,809 $16.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $546,228 - $985,100	85,885 Added 6.69%	1,369,822 $11.3 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $6.04 Million - $9.9 Million	-858,531 Reduced 40.07%	1,283,937 $9.31 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $2.16 Million - $3.43 Million	259,598 Added 13.79%	2,142,468 $19 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $21.1 Million - $33.6 Million	1,731,710 Added 1145.61%	1,882,870 $23 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $5.96 Million - $12.7 Million	-596,501 Reduced 79.78%	151,160 $1.79 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $3.39 Million - $6.65 Million	-240,629 Reduced 24.35%	747,661 $14.2 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $25.9 Million - $39.6 Million	975,116 Added 7401.82%	988,290 $26.2 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $7.53 Million - $14 Million	-191,745 Reduced 93.57%	13,174 $541,000
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $5.75 Million - $13.1 Million	144,794 Added 240.82%	204,919 $8.61 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $1.63 Million - $5.07 Million	60,125 New	60,125 $4.22 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $2.82 Million - $3.73 Million	-100,361 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1.22 Million - $2.26 Million	65,830 Added 190.64%	100,361 $2.97 Million
Q1 2020 May 14, 2020	SELL	$14.88 - $32.78 $499,566 - $1.1 Million	-33,573 Reduced 49.3%	34,531 $685,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $95,442 - $159,789	4,897 Added 7.75%	68,104 $2.02 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $471,885 - $562,527	20,982 Added 49.69%	63,207 $1.44 Million
Q2 2019 Aug 15, 2019	BUY	$20.48 - $27.76 $228,843 - $310,190	11,174 Added 35.99%	42,225 $1.05 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $1.95 Million - $2.65 Million	-95,415 Reduced 75.45%	31,051 $150,000
Q1 2019 May 14, 2019	BUY	$19.43 - $26.41 $1.03 Million - $1.41 Million	53,223 Added 72.67%	126,466 $3.09 Million
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $1.33 Million - $2.33 Million	73,243 New	73,243 $1.67 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $9.74 Million - $12.7 Million	-310,109 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$29.84 - $44.08 $3.36 Million - $4.97 Million	-112,648 Reduced 26.65%	310,109 $10.3 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $1.08 Million - $1.55 Million	49,336 Added 13.21%	422,757 $13 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $5.9 Million - $8.97 Million	373,421	373,421 $8.97 Million

Others Institutions Holding EDIT

# of Institutions

247

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $166M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account